Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Jazz Pharmaceuticals ( (JAZZ) ).
On October 21, 2025, Jazz Pharmaceuticals and its subsidiaries reached a global settlement agreement with Avadel Pharmaceuticals to resolve all disputes, including ongoing patent infringement litigation. As part of the settlement, Jazz will grant Avadel licenses for its Lumryz product, while Avadel will pay royalties to Jazz and refrain from marketing certain products until 2028. Jazz will pay Avadel $90 million and waive certain royalties, expecting a pre-tax charge of approximately $90 million in Q3 2025. The agreement aims to dismiss pending legal proceedings and includes mutual releases of claims.
The most recent analyst rating on (JAZZ) stock is a Buy with a $180.00 price target. To see the full list of analyst forecasts on Jazz Pharmaceuticals stock, see the JAZZ Stock Forecast page.
Spark’s Take on JAZZ Stock
According to Spark, TipRanks’ AI Analyst, JAZZ is a Neutral.
Jazz Pharmaceuticals’ overall stock score reflects strong technical indicators and positive earnings call sentiment, tempered by valuation concerns and financial performance risks. The company’s revenue growth and upcoming regulatory milestones are promising, but profitability challenges and high leverage remain significant risks.
To see Spark’s full report on JAZZ stock, click here.
More about Jazz Pharmaceuticals
Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing pharmaceutical products that address unmet medical needs. The company operates in the healthcare industry, primarily offering treatments for sleep disorders, oncology, and other therapeutic areas.
Average Trading Volume: 743,173
Technical Sentiment Signal: Buy
Current Market Cap: $8.18B
For an in-depth examination of JAZZ stock, go to TipRanks’ Overview page.